- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Adjuvant Trifluridine/Tipiracil Benefit is Limited to Select Subgroups in MRD+ CRC
April 30th 2025, 8:15pm
Trifluridine/tipiracil showed a favorable safety profile and numerically improved DFS vs placebo in MRD-positive CRC.
Adagrasib Yields Early Efficacy in STK11- and KRAS G12C–Mutant NSCLC
April 30th 2025, 6:48pm
First-line adagrasib monotherapy demonstrated preliminary efficacy and tolerability in patients with SK11- and KRAS G12C–mutant NSCLC.
Neoadjuvant Botensilimab Plus Balstilimab Is Active, Safe Regardless of Mismatch Repair Status in Solid Tumors
April 30th 2025, 5:25pm
Botensilimab and balstilimab proved active and safe as neoadjuvant therapy in patients with mismatch repair–deficient and –proficient solid tumors.
Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC
April 30th 2025, 1:30am
Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.
Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer
April 29th 2025, 11:51pm
Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.
SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors
April 29th 2025, 11:08pm
A phase 1b trial examining SYN818 plus olaparib in patients with solid tumors will be conducted in the second half of 2025.
Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer
April 29th 2025, 10:38pm
Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.
Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma
April 29th 2025, 10:10pm
Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.
Invikafusp Alfa Generates Clinical Activity in Checkpoint Inhibitor–Resistant Solid Tumors
April 29th 2025, 9:41pm
Invikafusp alfa was active in unresectable, locally advanced or metastatic solid tumors resistant to immune checkpoint inhibitors.
Sequencing Regorafenib After Fruquintinib Improves OS in mCRC
April 29th 2025, 8:34pm
Initial fruquintinib followed by regorafenib extended OS vs the reverse sequence of the agents in patients with metastatic colorectal cancer.
ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML
April 29th 2025, 8:21pm
A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.
Padeliporfin VTP Therapy Yields Complete Responses With Manageable Safety in Low-Grade, Upper Tract Urothelial Cancer
April 29th 2025, 8:17pm
American Urological Association Annual Meeting
Padeliporfin vascular targeted photodynamic therapy was safe and generated responses in low-grade, upper tract urothelial cancer.
Prospective, Real-World Study Highlights Feasibility of Outpatient Robotic Partial Nephrectomy in Renal Tumors
April 29th 2025, 8:05pm
American Urological Association Annual Meeting
A high proportion of patients with renal tumors were discharged on the same day after receiving robotic partial nephrectomy.
Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases
April 29th 2025, 7:45pm
Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.
Addition of Relatlimab/Nivolumab to Azacitidine/Venetoclax Shows Safety, Early Efficacy in Adverse-Risk Frontline AML
April 29th 2025, 7:07pm
Although the combination of azacitidine alone plus relatlimab/nivolumab was deemed safe, it had limited efficacy in patients with relapsed/refractory AML.
Maintenance Fruquintinib Plus Capecitabine Is Active, Tolerable in RAS/BRAF Wild-Type mCRC
April 29th 2025, 7:00pm
Fruquintinib plus capecitabine demonstrated preliminary efficacy and safety as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer.
Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer
April 29th 2025, 6:00pm
Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.
Dr Scilipoti on the Value of Life Expectancy Assessments to Guide Prostate Cancer Treatment Strategies
April 29th 2025, 5:32pm
American Urological Association Annual Meeting
Pietro Scilipoti, MD, discusses the need for better life expectancy assessment to guide prostate cancer treatment strategies.
Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC
April 29th 2025, 5:25pm
American Urological Association Annual Meeting
Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.
Subgroup Data From ARANOTE Highlight rPFS Benefit of Darolutamide Plus ADT in Black Patients With mHSPC
April 29th 2025, 5:11pm
American Urological Association Annual Meeting
Darolutamide plus ADT improved rPFS in Black patients with metastatic hormone-sensitive prostate cancer treated in ARANOTE.